• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions?

作者信息

Chakraborty Rajshekhar, Majhail Navneet S, Anwer Faiz

机构信息

Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio.

Multiple Myeloma Program, Cleveland Clinic, Cleveland, Ohio.

出版信息

JAMA Oncol. 2019 Aug 1;5(8):1095-1096. doi: 10.1001/jamaoncol.2019.1598.

DOI:10.1001/jamaoncol.2019.1598
PMID:31246229
Abstract
摘要

相似文献

1
Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions?地诺单抗与唑来膦酸用于多发性骨髓瘤的骨靶向治疗：尚未解决的问题有哪些？
JAMA Oncol. 2019 Aug 1;5(8):1095-1096. doi: 10.1001/jamaoncol.2019.1598.
2
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.地舒单抗对比唑来膦酸在初诊多发性骨髓瘤骨病治疗中的应用：一项国际性、双盲、双模拟、随机、对照、3 期研究。
Lancet Oncol. 2018 Mar;19(3):370-381. doi: 10.1016/S1470-2045(18)30072-X. Epub 2018 Feb 9.
3
Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.地诺单抗与唑来膦酸对骨转移癌患者钙水平的影响：一项回顾性队列研究。
J Oncol Pharm Pract. 2019 Dec;25(8):1846-1852. doi: 10.1177/1078155218820927. Epub 2019 Jan 7.
4
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.美国地诺单抗预防多发性骨髓瘤患者骨相关事件的成本效益分析。
J Med Econ. 2018 May;21(5):525-536. doi: 10.1080/13696998.2018.1445634. Epub 2018 Mar 5.
5
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.在一项随机3期试验中评估接受地诺单抗或唑来膦酸治疗的多发性骨髓瘤患者亚组的结果。
Blood Cancer J. 2016 Jan 8;6(1):e378. doi: 10.1038/bcj.2015.96.
6
The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.地舒单抗在预防转移性骨病癌症患者恶性高钙血症中的作用。
Eur J Cancer. 2015 Jul;51(11):1467-75. doi: 10.1016/j.ejca.2015.04.017. Epub 2015 May 11.
7
Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.地舒单抗与唑来膦酸预防脆弱性癌症患者骨骼相关事件的比较：一项随机对照试验的荟萃分析。
Clin Ther. 2020 Aug;42(8):1494-1507.e1. doi: 10.1016/j.clinthera.2020.05.019. Epub 2020 Jul 24.
8
[Management of bone disease in myeloma patients: zoledronic acid or denosumab?].[骨髓瘤患者骨病的管理：唑来膦酸还是地诺单抗？]
Rinsho Ketsueki. 2015 Aug;56(8):997-1004. doi: 10.11406/rinketsu.56.997.
9
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.晚期乳腺癌的骨相关并发症和生活质量：地舒单抗对比唑来膦酸的随机 III 期临床试验结果。
Clin Cancer Res. 2012 Sep 1;18(17):4841-9. doi: 10.1158/1078-0432.CCR-11-3310. Epub 2012 Aug 14.
10
[Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab].[从唑来膦酸转换为地诺单抗的多发性骨髓瘤患者的骨代谢标志物]
Rinsho Ketsueki. 2014 Nov;55(11):2271-6.

引用本文的文献

1
Treatment and disease-related complications in multiple myeloma: Implications for survivorship.多发性骨髓瘤的治疗和与疾病相关的并发症：对生存状况的影响。
Am J Hematol. 2020 Jun;95(6):672-690. doi: 10.1002/ajh.25764. Epub 2020 Mar 13.
2
Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple Myeloma.多发性骨髓瘤的 Medicare 受益人群中使用骨修饰药物的情况。
JAMA Oncol. 2020 Feb 1;6(2):296-298. doi: 10.1001/jamaoncol.2019.5426.